Atherothrombosis remains the leading cause of morbidity and mortality in patients diagnosed with diabetes mellitus, but the molecular mechanisms underpinning this remain unresolved. As the liver plays a major role in metabolic homeostasis and secretion of clotting factors and inflammatory innate immune proteins, there is an interest in understanding the mechanisms of hepatic cell activation under hyperglycemia and whether this can be attenuated pharmacologically. We have previously shown that hyperglycemia stimulates major changes in chromatin organisation and metabolism in hepatocytes, and that the histone deacetylase inhibitor valproic acid (VPA; IUPAC: 2-propylpentanoic acid) is able to reverse some of these metabolic changes. In this study, we used deep transcriptome sequencing to show that VPA attenuates hyperglycemia-induced activation of complement and coagulation cascade genes. These findings reveal a novel mechanism of VPA protection against hyperglycemia, which might improve the therapeutic approaches for diabetes.
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Hyperglycemia induces an inflammatory, prothrombotic state in diabetic patients but the underlying mechanisms remain poorly understood. Felisbino et al, use transcriptomics to identify molecular pathways upregulated by hyperglycemia in hepatocytes, and show that valproic acid attenuates the activation of coagulation and complement genes, which may be useful to reduce cardiovascular risk in diabetes patients.
INTRODUCTION
Diabetes is a multifactorial disorder with several pathways implicated in the development of diabetic micro-and macro-vascular complications.
[1] Macrovascular complications include atherosclerosis, cerebrovascular disease and peripheral vascular disease; for which diabetic patients have a two-to four-fold greater risk than non-diabetic individuals. [2] In diabetes, a combination of hyperglycemia, inflammation, oxidative stress and insulin resistance converge to produce a prothrombotic milieu, characterised by endothelial dysfunction, coagulative activation and platelet hyperreactivity. [3] Several important coagulation pathway proteins are elevated by hyperglycemia in vivo including fibrinogen, prothrombin 1 and 2, tissue factor, thrombin-antithrombin complexes, plasminogen activator inhibitor-1, tissue plasminogen activator and complement C3 which contribute to this hypercoagulative state. [4, 5] This prothrombotic state state appears to occur simultaneously with and may be dependent upon chronic low-grade inflammation and oxidative stress observed in diabetes. [6] Complement cascade proteins are a proposed source of inflammation in diabetes that are produced by monocytes, macrophages and hepatocytes. These proteins function in innate antimicrobial defense primarily through membrane attack and phagocyte recruitment, that are elevated in diabetes and suspected to contribute to diabetic complications. [7] The liver is the main site of production of circulating coagulation and complement proteins, and responsible for production of bile, cholesterol, decomposition of red blood cells and detoxification of xenobiotics and secondary metabolites. Of key importance for diabetes, liver hepatocytes play a major role in energy homeostasis by storing carbohydrates as glycogen during hyperglycemia and releasing sugars during hypoglycemia. Liver dysfunction, classified as elevated hepatic glucose production during hyperglycemia, is common in type-2 diabetes, and inhibiting this is a major mechanism of action of the widely prescribed glucose lowering drug metformin. We have previously shown that treatment of HepG2 human hepatocytes with the HDACis Trichostatin A (TSA) and VPA attenuated hepatic glucose production, although no significant difference was detected in global chromatin structure and epigenetic landscape.
Chromatin alterations promoted by HDACi under hyperglycemia may be a function of the differently regulated nuclear domains and genes rather than of global remodeling.
[12]
Therefore, identification of genes impacted by HDAC inhibition is paramount to a comprehensive understanding of its mechanisms of action and therapeutic target in amelioration of hyperglycemic state.
[ 15] We hypothesise that hepatocytes undergo major gene expression alterations when exposed to a hyperglycemic environment as the liver is an organ of critical importance to carbohydrate metabolism. Furthermore, we hypothesised that VPA could attenuate some of the deleterious pathways promoted by hyperglycemia.
In this study, HepG2 cells exposed to high-glucose (HG) were stimulated with VPA. We performed high throughput RNA-sequencing (RNA-seq) to understand transcriptome-wide analysis of of genes and pathways in response to hyperglycemia and VPA. This work identified that complement and coagulation pathways activated by hyperglycemia were strongly attenuated by HDAC inhibition. This work suggests a new avenue of action of VPA that might be relevant to the management of diabetes.
RESULTS

Hyperglycemia severely impacts hepatocyte gene expression
In order to understand the effect of high glucose on whole genome hepatic gene expression and function, RNA-seq was performed in HepG2 cells stimulated by hyperglycemic conditions in triplicate. After read alignment and gene expression quantification, statistical analysis of genes and pathways was undertaken. Multidimensional scaling analysis measures the similarity of the samples and projects this on two-dimensions. We observe low glucose (LG) and high glucose (HG) samples clustered into distinct groups ( Figure 1A ). Statistical analysis showed that HG treatment had a strong effect on HepG2 cells, with 4,259 genes showing differential expression (FDR≤0.05; Figure 1B -red points). This effect is much higher than that reported for high glucose treated monocytes [29] and endothelial cells [30] suggesting that hepatic cells are sensitive to changes in carbohydrate supply. LG, low glucosenormoglycemic condition. HG, high glucose -hyperglycemic condition. MANF , whose protein promotes survival of dopaminergic neurons, possibly playing a role in ER stress response; HSPA5 (aka GRP78 ), which encodes a glucose sensing protein, whose expression is upregulated by glucose starvation and is also present in the ER; CALR , that encodes calreticulin, a major calcium storage protein in the ER; DNAJB11 , which encodes yet another ER localized protein that acts as a chaperone for a number of partners. The glucose transporter gene SLC2A1 , encoding GLUT1 was also strongly down-regulated.
Gene Set Enrichment Analysis (GSEA) was used in order to understand pathways regulated by hyperglycemia. From 575 REACTOME gene sets considered, 34 
VPA treatment attenuates the expression of hyperglycemic response genes
Given that hyperglycemia induces major changes to the hepatocyte transcriptome and activates pathways relevant to cardiovascular health (such as cholesterol metabolism and complement/clotting cascades) and our previous work shows that VPA attenuates hepatic function, we hypothesised that VPA might inhibit hyperglycemic gene expression signatures.
Multidimensional scaling analysis shows that samples cluster based on treatment group. Untreated samples (LG, HG) are clearly separated from VPA-treated samples (LGV, HGV); and normoglycemic samples (LG, LGV) are separated from hyperglycemic ones (HG, HGV) ( Figure   3A ). Smear plot shows that 7,802 genes were altered in expression due to VPA treatment under hyperglycemia ( Figure 3B ). This plot also shows genes with initially low expression were upregulated after VPA treatment; on the other hand, genes initially highly expressed were down-regulated. Heatmap of top 50 genes by significance shows that the majority were upregulated ( Figure 3C ). LG, low glucose -normoglycemic condition. LGV, normoglycemic condition followed by VPA treatment. HG, high glucose -hyperglycemic condition. HGV, hyperglycemic condition followed by VPA treatment Figure 4B,C) . The regulation of all genes in response to glucose and VPA was visualised on a two dimensional rank-rank plot ( Figure 4D ). We observe that overall, genes are distributed relatively evenly among the four quadrants.
Using rank-rank visualisation of clotting and complement cascade genes we observed coordinated upregulation of these genes with hyperglycemia and attenuation by VPA ( Figure   4E ,F). The FDR corrected MANOVA p-values for the two-dimensional association were 2.0E-4 and 1.5E-7 for clotting and complement cascades respectively. LG, low glucose -normoglycemic condition. LGV, normoglycemic condition followed by VPA treatment. HG, high glucosehyperglycemic condition. HGV, hyperglycemic condition followed by VPA treatment. *, p<0.05; **, p<0.01; ***p<0.001 as depicted by one-way anova analysis.
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DISCUSSION
Metabolic syndromes and associated cardiovascular complications are a major health burden, but still, we have limited information on how deleterious stimuli such as hyperglycemia impact gene regulation in different organs, tissues and cells of the body. As the liver plays a major role in energy homeostasis, we hypothesised that hepatocytes would demonstrate robust gene expression changes in response to hyperglycemia, some of which could be deleterious to cardiovascular health. Furthermore, we hypothesised that HDAC inhibition via VPA could reverse or attenuate some of these gene pathways.
We used high throughput RNA sequencing (RNA-seq) for its unbiased ability to detect all expressed genes with greater sensitivity and accuracy than gene expression microarrays. With appropriate bioinformatics tools, regulatory events to genes and pathways (sets of genes) can be pinpointed in a way that is more efficient than single-gene assays. These tools were applied to identify genes and pathways that respond to hyperglycemia and/or VPA in hepatocytes.
The major gene sets upregulated by hyperglycemia were related to cholesterol metabolism, DNA replication and complement cascade and clotting cascades. The observation of elevated expression of clotting and complement factors is consistent with reports of these proteins being elevated in patients with diabetes. Interestingly, of these pathways, only complement cascade and clotting cascades were attenuated by VPA, as demonstrated by our two dimensional pathway analysis.
The complement system is a central component of innate immunity against microorganisms and modulator of inflammatory processes; it comprises a complex and tightly Felisbino et al, 2018 VPA attenuates hyperglycemic response regulated group of proteins involving various soluble and surface-bound components. Depending on the activation trigger, the complement cascade follows one of three pathways: classical, lectin or alternative.
[31] Although these pathways differ in their mechanisms of target recognition, all converge in the activation of the central component C3. This process is followed by C5 cleavage and the assembly of the pore-like membrane attack complex, MAC. Important chemoattractants and inflammatory mediators are produced by the enzymatic cleavage of C3 and C5, which leads to the release of anaphylatoxins C3a and C5a.
[32]
Together with complement, the coagulation system is the major blood-borne proteolytic cascade.
[33] Upon activation of the coagulation cascade, a sequential series of serine protease-mediated cleavage events occur. Thrombin is activated from its zymogen prothrombin and then catalyze the polymerization of fibrin by cleaving small peptides from its subunits. This way, soluble fibrinogen is converted into insoluble fibrin, which allows the clot formation.
[34]
Thrombin also plays a key role in amplifying the cascade by feedback activation of coagulation factors. [35] Other components as circulating red and white blood cells, and platelets are incorporated into the clot structure. In addition, factor XIIIa, which is also activated by thrombin, provides further structural stability by cross-linking with fibrin. [36] In this context, weak clots are more susceptible to fibrinolysis and bleeding, while resistant clots may promote thrombosis.
Coagulation and complement cascades share a common evolutionary origin [33] and their interplay is highlighted by C3, C4, C5a and FB complement protein presence in thrombus, [37] also procoagulation enzymes thrombin and IXa, Xa, XI factors might activate complement cascade.
[38] Moreover, MASP2, a component of lectin complement activation, is capable of [41]
Liver, mainly hepatocytes, is responsible for the biosynthesis and secretion of the majority of complement and coagulation components. Furthermore, the promoter regions of these components are controlled by several common liver-specific transcription factors like HNFs and C/EBP.
[42 ] Thomas and co-workers Thus, a common transcription factor network may be controlling the immune system and metabolism pathways. [49,50] MASP-1 and MASP-2 levels are found at significantly higher levels in children and adults with T1DM than in their respective control groups, whereas these proteins levels decreased when glycemic control improved.
[51]
Metabolic syndrome, including diabetes mellitus , is also frequently associated with a procoagulant state, in which the clotting system is switched toward a prothrombotic state, involving reduced fibrinolysis, increased plasmatic coagulation, and platelet hyperactivity. Intensive glycemic control with insulin reduces the impact of this procoagulant state by affecting components of the clotting pathway.
[53] Abnormalities in the coagulation and fibrinolytic systems contribute to the development of cardiovascular complications in patients with metabolic syndrome [35] and consistent lowering of clotting factors are used for the treatment of acute cardiovascular syndromes.
[54]
As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream pharmacological intervention in inflammatory diseases. [55] In this context, repurposing clinically approved drugs such as VPA provides a time-and cost-effective alternative.
CONCLUSIONS
In this work we could, for the first time, associate HDAC inhibition with complement and coagulation gene expression modulation, confirming that coagulation and complement cascade genes were upregulated by hyperglycemia and that these can be attenuated with VPA. If confirmed by pre-clinical and clinical in vivo assays, these findings have the potential to improve the therapeutic approaches for diabetes treatment. 
RNA isolation
Cells were disrupted with TRIzol (Qiagen, Hilde, Germany). RNA was isolated from TRIzol homogenates using the Direct-zol Kit (Zymo Research, Irvine, USA). RNA was quantified on Qubit (Thermo Fisher, Waltham, USA) and its quality was evaluated on the MultiNA bioanalyzer (Shimadzu, Kyoto, Japan).
mRNA sequencing
NEBNext® Poly(A) mRNA Magnetic Isolation Module was used to enrich mRNA from 1 μg of total RNA. We used the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (San Diego, USA) to generate barcoded libraries. Libraries were quantified on the MultiNA bioanalyzer (Shimadzu) and pooled to equimolar ratios for sequencing.
Cluster generation was performed at a concentration of 10 pM (TruSeq SR Cluster Kit v3-cBot-HS) and the flow cell was run on Illumina HiSeq2500 generating 50 nt reads at AGRF Melbourne. Sequence data has been deposited to NCBI Gene Expression Omnibus under accession number GSE109140.
Bioinformatics analysis
mRNA-seq data processing
Low quality bases (Qscore < 20) were removed from the 3' end with FASTX Toolkit v0.0.13. Trimmed reads less than 20 nt were also discarded. The human genome sequence and annotation (GRCh37.75) set were downloaded from the Ensembl website ( www.ensembl.org/info/data/ftp ). Reads were aligned using STAR version 2.3.1p_r359.
[56]
Sorted bam files were generated with SamTools (version 0.1.19-44428cd).
[57] A gene expression count matrix was generated with featureCounts v1.4.2 [58] using a map quality threshold of 10.
Genes with an average of fewer than 10 reads per sample were omitted from downstream analysis.
Statistical analysis of gene expression
EdgeR version 3.6.8 and limma version 3.20.9 were used to perform statistical analysis.
[59] False discovery rate controlled p-values (FDR)≤0.05 were considered significant.
Pathway analysis
Gene expression of pathways was analyzed with GSEA-P using the classic mode.
[60] A differential abundance score was obtained for each gene by dividing the sign of the fold change by the log10(p-value). This score was used to rank genes from most up-regulated to most down-regulated as described previously.
[15] Curated gene sets were downloaded from MSigDB.
[61]
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Integrative analysis
To understand the correlation between effects of VPA and hyperglycemia on global gene expression, we generated a rank-rank density plot of each detected gene. Genes were ranked as above and plotted using the filled contour plot function in R. Significance of two dimensional enrichment of gene sets away from a uniform distribution was calculated Manova test of ranks in R as described previously. [62] Real time quantitative PCR To validate some differentially expressed genes from the RNA-seq findings, we repeated the experiment using the same conditions of cell culture and treatment, isolated total RNA using the RNeasyMini Kit (Qiagen, Hilden, Germany) and prepared cDNA using the High-Capacity Relative quantification was achieved with the comparative 2-ΔΔCt method as described previously.
[63]
